Approved indication: Qbrexza is approved for the topical treatment of primary axillary hyperhidrosis (excessive underarm sweating not due to another medical cause) in adults and children 9 years and older.

Off-label uses: Some clinicians may use topical anticholinergic products such as glycopyrronium or glycopyrrolate off-label for excessive sweating on other body areas (for example hands, feet, or face), but Qbrexza itself is only studied and recommended for underarm use, and evidence for other sites is limited to small studies and case reports; safety and dosing for non-axillary use are not established.

Efficacy expectations:

• In clinical trials, about half to two-thirds of patients using Qbrexza once daily achieved a large, meaningful reduction in sweating after 4 weeks, compared with about one-quarter of patients using placebo cloths.
• Many patients notice some improvement within the first week of daily use, with maximum benefit usually seen by around 4 weeks; continued treatment can maintain benefit long term for many people.
• Compared with doing nothing, Qbrexza clearly reduces sweat and improves quality of life; compared with other treatments, it is less invasive than underarm Botox injections and more convenient than repeated procedures, but high-strength aluminum chloride antiperspirants or Botox may provide stronger sweat reduction for some patients.

Typical dosing: For adults and children 9 years and older, the usual dose is one single-use Qbrexza cloth applied once daily to both underarms; do not use more than once every 24 hours.

How to apply:

• Start with clean, completely dry, unbroken skin in each underarm.
• Carefully tear open one pouch, unfold the cloth, and wipe it across one entire underarm once, then use the same cloth to wipe across the other underarm once.
• Do not use the cloth on other body areas, on irritated or broken skin, or under occlusive dressings or plastic wraps.
• Let the underarms dry, discard the used cloth in the trash, and wash your hands well with soap and water to avoid transferring medicine to your eyes or face.
• Apply at about the same time each day (many people use it in the evening), following your prescriber’s instructions.

Special dosing instructions: Your clinician may suggest less frequent application (for example, every other day) if you have bothersome anticholinergic side effects such as dry mouth or blurred vision; never use more than one cloth at a time or apply extra to “catch up.”

Missed dose guidance: If you miss a dose, apply it as soon as you remember unless it is almost time for your next dose, in which case skip the missed dose and resume your regular schedule; do not use two cloths at once or on the same day to make up for a missed application.

Overdose or accidental exposure: Using more than directed, applying to large or multiple body areas, or accidental swallowing can increase the risk of serious anticholinergic toxicity (severe dry mouth, fast heartbeat, high temperature, confusion, trouble urinating, or marked blurred vision); in these situations, seek emergency medical care or contact a poison control center right away.

Common side effects: Most side effects are related to anticholinergic effects or local skin irritation and are usually mild to moderate.

• Dry mouth, throat, nose, eyes, or skin.
• Dilated pupils and blurred vision, especially if the medicine gets near the eyes.
• Local underarm reactions such as redness, burning or stinging, and itching.
• Headache, constipation, or mild urinary hesitation or difficulty starting urination.

Serious or rare adverse effects: These are less common but need prompt medical attention.

• Inability to empty the bladder (urinary retention), with a very full or painful lower abdomen and little or no urine output.
• Problems controlling body temperature, such as feeling very hot, little or no sweating over much of the body, hot red skin, confusion, or fainting, especially in hot weather or with heavy exercise.
• Severe or sudden eye pain, vision changes, or halos around lights, which could signal a serious eye problem in someone at risk for narrow-angle glaucoma.
• Signs of a severe allergic reaction, such as hives, trouble breathing, or swelling of the face, lips, tongue, or throat.

Warnings and precautions:

• Existing conditions: Use is generally avoided or used with great caution in people with conditions that can be worsened by anticholinergics, such as narrow-angle glaucoma, urinary retention or significant bladder outlet obstruction, certain severe bowel diseases (severe ulcerative colitis, toxic megacolon, paralytic ileus), myasthenia gravis, or Sjögren’s syndrome.
• Heat and exercise: Because Qbrexza reduces sweating, it can increase the risk of overheating; patients should avoid becoming very overheated or dehydrated and stop the medication and seek care if they develop signs of heat illness.
• Vision and activities: If blurred vision occurs, patients should stop using Qbrexza until it resolves and avoid driving or operating machinery while vision is affected.
• Pregnancy and breastfeeding: Human data are very limited; there is no clear information on risk in pregnancy or while breastfeeding, so clinicians usually use it only if the expected benefit clearly outweighs potential risk, avoid application on or near the breast, and ensure infants do not contact treated skin.
• Age considerations: Safety and effectiveness are established for patients 9 years and older; it is not recommended in younger children, and older adults may be more sensitive to anticholinergic side effects.
• Kidney or liver disease: Because glycopyrronium is cleared largely by the kidneys, significant kidney impairment may increase systemic exposure and side effects, so extra caution and close monitoring are advised; no specific adjustment is defined for liver disease, but prescribers individualize use.

Overall safety profile: Compared with oral anticholinergic pills, Qbrexza generally produces fewer whole-body side effects because it is applied only to the underarms, but systemic effects like dry mouth, blurred vision, and urinary symptoms are still relatively common and can limit use for some patients.

Reporting side effects and updates: Patients should tell their prescriber about any bothersome or unexpected effects; in the United States, side effects can also be reported to FDA MedWatch by phone at 1-800-FDA-1088, and updated safety information is available through the FDA and the medication’s patient information leaflet.

Drug and supplement interactions:

• Other anticholinergic medicines: Combining Qbrexza with other anticholinergic drugs (such as some antihistamines, overactive bladder medicines, tricyclic antidepressants, certain antipsychotics, motion-sickness medicines, or Parkinson’s drugs) can significantly increase side effects like dry mouth, constipation, blurred vision, and urinary retention, so this combination is generally avoided or used only with careful monitoring.
• Medicines that already cause constipation or urinary problems: Opioid pain medicines and other drugs that slow the gut or make urination difficult can have additive effects with Qbrexza, increasing the risk of severe constipation or urinary retention.
• Herbal products and supplements: Products with anticholinergic properties (for example, belladonna-containing herbal blends) may intensify side effects; patients should review all supplements with their clinician.
• Food, alcohol, and imaging: No specific food interactions are known; alcohol does not appear to directly interact but can worsen dehydration and dizziness, so moderation is advised; Qbrexza is not known to interfere with routine blood tests or imaging, but patients should still tell radiology staff and other healthcare providers that they use it.

Conditions and co-medications requiring extra caution:

• History of urinary retention, significant prostate enlargement, or bladder outlet obstruction.
• Narrow-angle glaucoma or being at risk for angle-closure glaucoma.
• Severe bowel diseases or obstruction, including severe ulcerative colitis, toxic megacolon, or paralytic ileus.
• Neuromuscular or autoimmune conditions such as myasthenia gravis or Sjögren’s syndrome.
• Significant kidney impairment or multiple other anticholinergic medicines that raise total anticholinergic burden.
• Very hot environments, heavy exercise, or occupations where overheating is a concern.

Monitoring needs:

• Watch for systemic anticholinergic effects such as troublesome dry mouth, severe constipation, blurred vision, or urinary difficulties, especially in the first weeks of therapy or after dose-frequency changes.
• Monitor for signs of impaired temperature regulation, including reduced sweating over much of the body, feeling excessively hot, or heat illness symptoms in warm environments.
• Check underarm skin regularly for redness, burning, stinging, or rash; persistent or severe irritation should be discussed with a clinician.
• Patients with complex medical conditions or many other medications may need closer follow-up to reassess tolerability and interaction risk.

Q: What is Qbrexza used for?
A: Qbrexza is a prescription medicated cloth used once daily on the underarms to reduce excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

Q: How long does it take for Qbrexza to start working?
A: Some people notice less sweating within the first week of daily use, but it often takes about 4 weeks of consistent treatment to see the full benefit.

Q: Can I use Qbrexza on my hands, feet, or face?
A: Qbrexza is approved and recommended only for the underarm area, and using it on other body parts is not advised unless a specialist specifically directs this, because safety and dosing for other sites are not well established.

Q: Will Qbrexza cure my hyperhidrosis?
A: Qbrexza helps control symptoms while you use it, but it does not cure hyperhidrosis, so sweating usually returns if treatment is stopped.

Q: Is Qbrexza safer than taking oral anticholinergic pills?
A: Because Qbrexza is applied only to the underarms, it generally causes fewer whole-body anticholinergic effects than oral pills, but side effects like dry mouth, blurred vision, and urinary symptoms can still occur and should be monitored.

Q: What if I still sweat a lot while using Qbrexza?
A: If sweating remains bothersome after several weeks of correct daily use, talk with your clinician, who may adjust how often you use it, add or switch to other treatments such as stronger antiperspirants, Botox injections, or systemic medicines, or reassess for other causes of sweating.

Storage: Store Qbrexza pouches at room temperature, in a dry place away from moisture, direct sunlight, and heat; keep each cloth sealed in its pouch until use, and avoid storing or using it near open flame or while smoking because the cloths are flammable.

Safety: Keep all unopened and used pouches out of the reach of children and pets, and do not use the cloths if the pouch is torn or damaged.

Disposal: After applying, place the used cloth and empty pouch in the household trash out of reach of children and animals, do not flush them down the toilet, and ask your pharmacist or local waste program how to discard any unused or expired medication.